News | May 01, 2025
Briefs: Alembic Pharmaceuticals and Bafna Pharmaceuticals
Alembic Pharmaceuticals commissions new facility at Pithampur
Alembic Pharmaceuticals commissions new facility at Pithampur
This approval authorizes the company to export Ibuprofen to the Chinese markets
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
According to IQVIATM sales data for the 12-month period ending February 2025, the Adderall Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market3 achieved annual sales of approximately $421.7 million.
Mantri will replace V. S. Mani, Executive Director & Global Chief Financial Officer of the company as he has conveyed his decision to opt for early retirement
According to IQVIA sales data for the 12-month period ending January 2025, the Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) market achieved annual sales of approximately $39.3 mn
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
Alembic Pharmaceuticals successfully completes USFDA inspection for API-III facility
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant
Subscribe To Our Newsletter & Stay Updated
